Lebrikizumab-Treated Patients With Atopic Dermatitis Had No Increase in Treatment-Emergent Adverse Events of Facial, Head, and Neck Erythema Compared to Placebo. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 7, n. 6, p. s272, 2023. DOI: 10.25251/skin.7.supp.272. Disponível em: https://skin.dermsquared.com/skin/article/view/2383. Acesso em: 24 oct. 2025.